NCT02269930View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Multiple Sclerosis
Interventions
DRUG

peginterferon beta-1a

Administered as subcutaneous injection

DRUG

Rebif

Administered as subcutaneous injection

Trial Locations (1)

47710

Research Site, Evansville

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY